Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel PK/PD in Chemotherapy-Naive CRPC
NCT01666314Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orteronel in castration-resistant prostate cancer (CRPC) (8 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Percentage of Participants With Serum Testosterone Levels Reduced to ≤ 2 ng/dL After 4 Weeks of Treatment in Japan. Started Aug 2012; status: completed.
02
Drugs
orteronel
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01666314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666314.